Founded in 1878 and based in Osaka, Japan, Shionogi is a drug-discovery-based ... Several of these dangerous bugs feature on both the World Health Organization and the US Centers for Disease ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...

Shionogi has been awarded $375m by the US Department of Health and Human Services (HHS) to develop a long-acting therapeutic aimed at protecting vulnerable populations from Covid-19. The funding ...

Shares in Shionogi & Co posted their steepest fall in three months on Thursday after a health ministry panel again delayed emergency approval for the Japanese drugmaker's oral treatment against ...

Shionogi has also discovered important antiviral products and has therapeutic ... Appropriate use initiatives, including stewardship by health-care practitioners, aim to slow the rate of ...

The health ministry on Nov ... The oral drug Xocova marks the first home-grown medication, developed by Shionogi & Co., which can be prescribed for patients with mild symptoms, suggesting a ...

Shionogi filed an application on Feb. 25 for health ministry approval for manufacturing and selling its oral COVID-19 pill--the first domestic drug company to do so. The ministry has reviewed the ...

Digital health company Akili is on the brink of its first major expansion beyond the US, partnering with Shionogi to file a localised version of its attention deficit hyperactivity disorder (ADHD ...

Iwasaki attributed the decision to shifts in business strategies and emphasized that Shionogi will focus on ... billion for COVID-19 and influenza products combined. Analysts expressed skepticism ...

“COVID-19 continues to be a serious global health risk even with ... of society by developing new products and services to address this pandemic. Shionogi is committed to equitable access ...